Kiromic Biopharma Inc (NASDAQ:KRBP) — Market Cap & Net Worth
Market Cap & Net Worth: Kiromic Biopharma Inc (KRBP)
Kiromic Biopharma Inc (NASDAQ:KRBP) has a market capitalization of $214.93K ($214.93K) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #31105 globally and #6192 in its home market, demonstrating a 3.24% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kiromic Biopharma Inc's stock price $22.07 by its total outstanding shares 2653480 (2.65 Million). Review Kiromic Biopharma Inc (KRBP) total liabilities to assess the company's total debt and financial obligations.
Kiromic Biopharma Inc Market Cap History: 2020 to 2026
Kiromic Biopharma Inc's market capitalization history from 2020 to 2026. Data shows change from $674.25 Million to $58.55 Million (-38.42% CAGR).
Kiromic Biopharma Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kiromic Biopharma Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of KRBP by Market Capitalization
Companies near Kiromic Biopharma Inc in the global market cap rankings as of June 18, 2026.
Key companies related to Kiromic Biopharma Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
Kiromic Biopharma Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Kiromic Biopharma Inc's market cap moved from $674.25 Million to $ 58.55 Million, with a yearly change of -38.42%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $58.55 Million | +54651.86% |
| 2025 | $106.94K | -95.52% |
| 2024 | $2.39 Million | +3.45% |
| 2023 | $2.31 Million | -83.95% |
| 2022 | $14.38 Million | -88.34% |
| 2021 | $123.39 Million | -81.70% |
| 2020 | $674.25 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Kiromic Biopharma Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $214.93K USD |
| MoneyControl | $214.93K USD |
| MarketWatch | $214.93K USD |
| marketcap.company | $214.93K USD |
| Reuters | $214.93K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Kiromic Biopharma Inc
Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, engages in the utilization of non-engineered an engineered allogeneic Gamma Delta T (GDT) cell technologies to develop therapies for solid tumors in the United States. The company's lead product candidate is the Deltacel-01, which is in Phase 1 clinical trial, in combination with low-dose targeted radiation for patients with non-s… Read more